Journal

Disease markers
ISSN: 1875-8630
Titre abrégé: Dis Markers
Pays: United States
ID NLM: 8604127

Informations de publication

Date de publication:
2019
Historique:
received: 30 07 2019
revised: 16 10 2019
accepted: 26 11 2019
entrez: 14 1 2020
pubmed: 14 1 2020
medline: 12 5 2020
Statut: epublish

Résumé

Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver diseases. Obesity is the most common and well-established risk factor for NAFLD, but there are large interindividual differences in the relationship between weight status and the development of NAFLD. Beta-3-adrenergic receptor (ADRB3) plays a key role in the development of visceral obesity and insulin resistance; however, the effect of

Identifiants

pubmed: 31929840
doi: 10.1155/2019/4065327
pmc: PMC6942826
doi:

Substances chimiques

ADRB3 protein, human 0
Genetic Markers 0
Receptors, Adrenergic, beta-3 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4065327

Informations de copyright

Copyright © 2019 Yuki Sakamoto et al.

Déclaration de conflit d'intérêts

The authors declare that they have no conflict of interest.

Références

Dis Markers. 2018 Sep 23;2018:8635329
pubmed: 30344796
Science. 2002 Aug 2;297(5582):843-5
pubmed: 12161655
Cells. 2019 Apr 16;8(4):
pubmed: 30995798
Int J Mol Sci. 2016 Jul 22;17(7):
pubmed: 27455252
J Hepatol. 2017 Oct;67(4):862-873
pubmed: 28642059
N Engl J Med. 1995 Aug 10;333(6):348-51
pubmed: 7609751
N Engl J Med. 1995 Aug 10;333(6):352-4
pubmed: 7609752
J Clin Invest. 1993 Jan;91(1):344-9
pubmed: 8380813
Nat Rev Gastroenterol Hepatol. 2017 Jan;14(1):32-42
pubmed: 27729660
Lipids Health Dis. 2018 Mar 27;17(1):58
pubmed: 29587766
Obes Res. 2001 Dec;9(12):741-5
pubmed: 11743057
Int J Obes Suppl. 2014 Jul;4(Suppl 1):S17-20
pubmed: 27152160
Diabetes Care. 2004 Jun;27(6):1487-95
pubmed: 15161807
Hypertens Res. 2019 Sep;42(9):1235-1481
pubmed: 31375757
J Endocrinol. 2016 Dec;231(3):259-269
pubmed: 27672060
Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):1-22
pubmed: 14647973
Diabetol Int. 2018 Mar 27;9(1):1-45
pubmed: 30603347
Lancet. 2004 Jan 10;363(9403):157-63
pubmed: 14726171
J Lipid Res. 2015 Oct;56(10):1912-25
pubmed: 26269358
J Diabetes Investig. 2016 May;7(3):338-42
pubmed: 27330719
J Gastroenterol. 2017 Feb;52(2):164-174
pubmed: 27637587
Lancet. 1995 Nov 25;346(8987):1433-4
pubmed: 7475854
Diabetes. 2018 Dec;67(12):2485-2493
pubmed: 30459251
Appl Physiol Nutr Metab. 2016 Mar;41(3):307-14
pubmed: 26888112
Diabetes. 1999 Jan;48(1):117-20
pubmed: 9892231
Rom J Morphol Embryol. 2009;50(2):169-79
pubmed: 19434307
Cardiovasc Diabetol. 2011 Oct 12;10:89
pubmed: 21992420
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
Cardiol Rev. 2013 Nov-Dec;21(6):265-9
pubmed: 23707990
J Gastroenterol Hepatol. 2012 Oct;27(10):1555-60
pubmed: 22741595
Gut. 2017 Jun;66(6):1138-1153
pubmed: 28314735
CPT Pharmacometrics Syst Pharmacol. 2018 Jun;7(6):384-393
pubmed: 29569850
Diabetes Care. 2015 Jan;38(1):150-8
pubmed: 25538311
Gastroenterology. 2014 Mar;146(3):726-35
pubmed: 24316260
J Atheroscler Thromb. 2018 Sep 1;25(9):846-984
pubmed: 30135334
J Clin Endocrinol Metab. 2013 Jul;98(7):E1272-7
pubmed: 23640967
Methods Mol Biol. 2017;1666:557-580
pubmed: 28980265
Metabolism. 2003 Sep;52(9):1096-101
pubmed: 14506613
Alcohol Clin Exp Res. 2004 Aug;28(8 Suppl Proceedings):106S-110S
pubmed: 15318095
EMBO J. 1991 Dec;10(12):3721-7
pubmed: 1718744
Gastroenterology. 2016 Jun;150(8):1769-77
pubmed: 26928243
Diabetologia. 1997 Apr;40(4):469-72
pubmed: 9112025
Environ Health Prev Med. 2010 Nov;15(6):392-7
pubmed: 21432572
Diabetes. 2017 Aug;66(8):2241-2253
pubmed: 28490610
Obes Res Clin Pract. 2011 Apr-Jun;5(2):e79-e156
pubmed: 24331062
Metabolism. 2008 Nov;57(11):1570-5
pubmed: 18940396
BMC Complement Altern Med. 2018 Jan 24;18(1):26
pubmed: 29361938
Diabetes Res Clin Pract. 2017 Jul;129:86-96
pubmed: 28521197
PLoS One. 2015 Jul 22;10(7):e0132640
pubmed: 26200108
Int J Obes (Lond). 2008 Aug;32(8):1240-9
pubmed: 18574485
N Engl J Med. 1995 Aug 10;333(6):343-7
pubmed: 7609750

Auteurs

Yuki Sakamoto (Y)

Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, Japan.

Kentaro Oniki (K)

Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, Japan.

Naoki Kumagae (N)

Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, Japan.

Kazunori Morita (K)

Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, Japan.

Koji Otake (K)

Japanese Red Cross Kumamoto Health Care Center, Kumamoto 861-8528, Japan.

Yasuhiro Ogata (Y)

Japanese Red Cross Kumamoto Health Care Center, Kumamoto 861-8528, Japan.

Junji Saruwatari (J)

Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, Japan.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH